Jul 7, 2020

A previously treated severe haemophilia A patient developed high-titre inhibitor after vaccinations

International Journal of Immunopathology and Pharmacology
Zekun LiRunhui Wu

Abstract

The factor VIII (FVIII)-neutralizing antibody (inhibitor) seen in 25%-30% of patients with severe haemophilia A (SHA). Vaccination is a non-genetic risk factor of inhibitor development as 'danger signal' which may provide a pro-inflammatory microenvironment to increase FVIII immunogenicity. We reported a previously treated SHA patient postponed the first vaccination to 15-month age received diphtheria-pertussis-tetanus intramuscularly. At 18-month age, the patient received Hepatitis A intramuscularly and Varicella Zoster Virus subcutaneously with 2 weeks interval and FVIII infusion was given <24 h prior for each. Successive bleedings occurred 1 week later with inefficacy of FVIII replacement. High-titre inhibitor was tested at 117 exposure days. This case suggested that continuous vaccinations in close proximity to FVIII could induce inhibitor. The relationship between vaccination and FVIII immunogenicity still needs to be revealed by further study.

  • References17
  • Citations

References

  • References17
  • Citations

Citations

  • This paper may not have been cited yet.

Mentioned in this Paper

Infusion Procedures
Hemorrhage
Study
Human herpesvirus 3
Inhibitors
F8
Severe Hereditary Factor Viii Deficiency Disease
Intramuscular
Vaccination
Proximal

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

© 2020 Meta ULC. All rights reserved